Go Pro

Abbott Laboratories (ABT) Stock Price, News & Analysis

Abbott Laboratories logo
$105.99 +0.29 (+0.27%)
Closing price 07/31/2026 03:59 PM Eastern
Extended Trading
$105.62 -0.36 (-0.34%)
As of 07/31/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Abbott Laboratories Stock (NYSE:ABT)

Advanced

Key Stats

Today's Range
$102.89
$106.39
50-Day Range
$85.36
$108.15
52-Week Range
$81.97
$137.49
Volume
9.61 million shs
Average Volume
12.75 million shs
Market Capitalization
$183.40 billion
P/E Ratio
34.30
Dividend Yield
2.38%
Price Target
$118.17
Consensus Rating
Moderate Buy

Company Overview

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability. The medical devices business includes cardiac and vascular products, structural heart therapies, neuromodulation and diabetes-care technologies, notably continuous glucose monitoring systems and insulin-delivery adjuncts. Abbott’s nutrition portfolio features infant formulas, adult nutritional supplements and pediatric nutrition brands designed for clinical and retail settings. The company’s established pharmaceuticals unit develops and markets a range of branded generic medicines in selected international markets.

Abbott has a long corporate history and has reshaped its business through strategic transactions, including a 2013 corporate separation that created AbbVie as an independent research-driven pharmaceutical company and a 2017 acquisition that broadened its medical-device offerings. These moves, together with ongoing investments in research and product development, reflect Abbott’s focus on innovation across diagnostics, devices, nutrition and pharmaceuticals.

Today Abbott serves a global footprint, with products marketed in many countries around the world. The company is led by President and Chief Executive Officer Robert B. Ford and maintains research, manufacturing and distribution operations to support healthcare providers, laboratories, retailers and consumers. Abbott emphasizes collaboration with the medical community and regulatory bodies to advance product availability and patient care worldwide.

AI Generated. May Contain Errors.

Abbott Laboratories Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
92nd Percentile Overall Score

ABT MarketRank™: 

Abbott Laboratories scored higher than 92% of companies evaluated by MarketBeat, and ranked 45th out of 894 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Abbott Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 3 strong buy ratings, 19 buy ratings, 3 hold ratings, and 1 sell rating.

  • Upside Potential

    Abbott Laboratories has a consensus price target of $118.17, representing about 11.5% upside from its current price of $105.99.

  • Amount of Analyst Coverage

    Abbott Laboratories has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Abbott Laboratories' stock forecast and price target.
  • Earnings Growth

    Earnings for Abbott Laboratories are expected to grow by 10.14% in the coming year, from $5.52 to $6.08 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Abbott Laboratories is 34.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.18.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Abbott Laboratories is 34.30, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 282.27.

  • Price to Earnings Growth Ratio

    Abbott Laboratories has a PEG Ratio of 2.05. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Abbott Laboratories has a P/B Ratio of 3.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Abbott Laboratories' valuation and earnings.
  • Percentage of Shares Shorted

    1.43% of the float of Abbott Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    Abbott Laboratories has a short interest ratio ("days to cover") of 2.14, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Abbott Laboratories has recently increased by 6.24%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Abbott Laboratories pays a meaningful dividend of 2.38%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Abbott Laboratories has been increasing its dividend for 54 years.

  • Dividend Coverage

    The dividend payout ratio of Abbott Laboratories is 81.55%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, Abbott Laboratories will have a dividend payout ratio of 41.45% next year. This indicates that Abbott Laboratories will be able to sustain or increase its dividend.

  • Read more about Abbott Laboratories' dividend.
  • News Sentiment

    Abbott Laboratories has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 56 news articles for Abbott Laboratories this week, compared to 10 articles on an average week.
  • Search Interest

    Only 68 people have searched for ABT on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.
  • MarketBeat Follows

    46 people have added Abbott Laboratories to their MarketBeat watchlist in the last 30 days. This is an increase of 360% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Abbott Laboratories insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    0.46% of the stock of Abbott Laboratories is held by insiders.

  • Percentage Held by Institutions

    75.18% of the stock of Abbott Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Abbott Laboratories' insider trading history.
Receive ABT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abbott Laboratories and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABT Stock News Headlines

Abbott (ABT) Stock Looks Like A Bargain Below Fair Value
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7. One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race.tc pixel
Erste Group Bank Has Positive Outlook of ABT FY2026 Earnings
AbbVie’s (NYSE:ABBV) Q2 CY2026: Beats On Revenue
Abbott logo displayed on a glass office building exterior at the company's headquarters.
Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
Abbott's Q2 results show solid organic growth, better-than-expected margins, and improved earnings guidance, easing concerns over the Exact Sciences acquisition and boosting ABT shares.
See More Headlines

ABT Stock Analysis - Frequently Asked Questions

Abbott Laboratories' stock was trading at $125.30 at the beginning of 2026. Since then, ABT shares have decreased by 15.4% and is now trading at $105.9870.

Abbott Laboratories (NYSE:ABT) issued its earnings results on Thursday, July, 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating analysts' consensus estimates of $1.28 by $0.03. The firm's revenue for the quarter was up 13.0% compared to the same quarter last year.
Read the conference call transcript
.

Abbott Laboratories subsidiaries include Cephea Valve Technologies, Alere, St. Jude Medical, Kalila Medical, Tendyne Holdings Inc., Veropharm, Topera Inc., and others.

Abbott Laboratories' top institutional shareholders include Assenagon Asset Management S.A. (0.18%), Mirae Asset Global Investments Co. Ltd. (0.11%), DAVENPORT & Co LLC (0.10%) and Alecta Tjanstepension Omsesidigt (0.09%). Insiders that own company stock include Daniel J Starks, Robert B Ford, Jr Robert E Funck, Jr Robert E Funck, Daniel Gesua Sive Salvadori, Mary K Moreland, Andrea F Wainer, Lisa D Earnhardt, Eric Shroff, Elizabeth C Cushman, John A Jr Mccoy and Philip P Boudreau.
View institutional ownership trends
.

Shares of ABT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Abbott Laboratories investors own include JPMorgan Chase & Co. (JPM), Chevron (CVX), NVIDIA (NVDA), Predictive Oncology (POAI), Bank of America (BAC), Meta Platforms (META) and AbbVie (ABBV).

Company Calendar

Record date for 5/15 Dividend
4/15/2026
Ex-Dividend for 5/15 Dividend
4/15/2026
Dividend Payable
5/15/2026
Record date for 8/17 Dividend
7/15/2026
Ex-Dividend for 8/17 Dividend
7/15/2026
Last Earnings
7/16/2026
Today
8/03/2026
Dividend Payable
8/17/2026
Next Earnings (Estimated)
10/21/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NYSE:ABT
CIK
1800
Employees
115,000
Year Founded
1888

Price Target and Rating

High Price Target
$143.00
Low Price Target
$92.00
Potential Upside/Downside
+11.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
26 Analysts

Profitability

EPS (Trailing Twelve Months)
$3.09
Trailing P/E Ratio
34.30
Forward P/E Ratio
19.20
P/E Growth
2.05
Net Income
$6.52 billion
Net Margins
11.65%
Pretax Margin
16.12%
Return on Equity
17.69%
Return on Assets
9.44%

Debt

Debt-to-Equity Ratio
0.57
Current Ratio
1.38
Quick Ratio
0.97

Sales & Book Value

Annual Sales
$44.33 billion
Price / Sales
4.14
Cash Flow
$7.01 per share
Price / Cash Flow
15.12
Book Value
$30.35 per share
Price / Book
3.49

Miscellaneous

Outstanding Shares
1,730,380,000
Free Float
1,722,423,000
Market Cap
$183.40 billion
Optionable
Optionable
Beta
0.59

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NYSE:ABT) was last updated on 8/3/2026 by MarketBeat.com Staff.
From Our Partners